Dan Junius, ImmunoGen CEO, discusses which drugs are in the company's pipeline, and weighs in on the outlook for the company, with Mad Money's Jim Cramer.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT